The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-positive, HER2-negative stage II and III patients to prevent recurrence. Administered orally, the drug is taken for three weeks followed by a one-week break over three years. Read the article to know more. The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-positive, HER2-negative stage II and III patients to prevent recurrence. Administered orally, the drug is taken for three weeks followed by a one-week break over three years. Read the article to know more. Health and Fitness, Health Tips, Exercises & Workout Tips, Diet & Wellness | Times of India Lifestyle
US FDA approves breast cancer drug Kisqali: All about it
